DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Zielinski C, Láng I, Inbar M. et al.
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Lancet Oncol 2016;
17: 1230-1239
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.